Hrt Financial LP Macrogenics Inc Transaction History

Hrt Financial LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$3.31 - $18.51 $248,389 - $1.39 Million	75,042 New	75,042 $318,000
Q3 2023 Nov 13, 2023	SELL	$4.48 - $6.19 $284,632 - $393,275	-63,534 Reduced 41.24%	90,540 $421,000
Q2 2023 Aug 11, 2023	SELL	$4.62 - $7.54 $359,680 - $587,011	-77,853 Reduced 33.57%	154,074 $824,000
Q1 2023 May 12, 2023	BUY	$4.82 - $7.24 $447,845 - $672,697	92,914 Added 66.84%	231,927 $1.66 Million
Q4 2022 Feb 10, 2023	SELL	$3.34 - $6.98 $101,445 - $212,003	-30,373 Reduced 17.93%	139,013 $932,000
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $495,554 - $859,399	-164,636 Reduced 49.29%	169,386 $586,000
Q2 2022 Aug 12, 2022	BUY	$2.25 - $9.99 $751,549 - $3.34 Million	334,022 New	334,022 $985,000
Q1 2022 May 16, 2022	SELL	$8.12 - $16.9 $595,163 - $1.24 Million	-73,296 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.91 - $21.88 $318,390 - $437,862	-20,012 Reduced 21.45%	73,296 $1.18 Million
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $1.84 Million - $2.68 Million	93,308 New	93,308 $1.95 Million
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $158,264 - $275,206	-7,724 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $146,678 - $256,436	7,724 New	7,724 $246,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.